Zhejiang Hisun Pharmaceutical Co., Ltd.

Xiangyang Zhang

Liang Zhang

Zhiqing Yang

Hongying Luo

Jian Chai

Jinyi Xu

Zhenjuan Shi

Hairong Luo

Di Su

Dejin Fu

Xinzeng Wang

Chuan Liu

Zhaozhao Zhang

Min Zhao

Zhi Chen

Provided are a new crystal form of fludarabine phosphate, a preparation method therefor, a pharmaceutical composition containing same, and an application thereof in preparing medicine. Crystal forms I and II of the fludarabine phosphate have excellent properties in terms of solubleness, dissolution rate, chemical stability, and processing adaptability.

Crystal form of fludarabine phosphate, preparation method therefor, and application thereof

Provided are crystal forms I, II, III and IV of a pyrroloquinoline quinone sodium salt and a preparation method thereof. Also provided are a pharmaceutical composition, a cosmetic composition, a functional food or a nutritional agent containing the above-mentioned crystal forms. The crystal forms have excellent properties in terms of solubility, crystal stability, hygroscopicity and the like.

Crystal form of pyrroloquinoline quinone sodium salt and preparation method and use thereof

Provided are crystal forms I, II, and III of bedaquiline fumarate, and preparation methods thereof. The crystal forms have high purity, excellent physicochemical properties, and good stability. The preparation methods can effectively improve the quality of products, and are applicable to preparation and mass production of medicines.

Crystal forms of bedaquiline fumarate and preparation methods therefor

The present invention relates to novel crystal forms M and N of dabigatran etexilate mesylate and preparation method and uses thereof, wherein the X-Ray powder diffractogram of the crystal form M has characteristic peaks at the following 2&#x3b8; diffraction angles: 5.7&#xb1;0.2&#xb0;, 6.2&#xb1;0.2&#xb0;, 11.2&#xb1;0.2&#xb0;, 12.4&#xb1;0.2&#xb0;, 18.2&#xb1;0.2&#xb0;, 21.4&#xb1;0.2&#xb0;, 21.8&#xb1;0.2&#xb0; and 23.6&#xb1;0.2&#xb0;; and the X-Ray powder diffractogram of the crystal form N has characteristic peaks at the following 2&#x3b8; diffraction angles: 6.0&#xb1;0.2&#xb0;, 11.8&#xb1;0.2&#xb0;, 18.2&#xb1;0.2&#xb0;, 21.6&#xb1;0.2&#xb0;, 24.4&#xb1;0.2&#xb0;, 27.7&#xb1;0.2&#xb0; and 29.7&#xb1;0.2&#xb0;. The crystal forms of the present invention have excellent properties in the aspects of leaching time, biological release, chemical stability and processing adaptability.

Crystal form of dabigatran etexilate mesylate and preparation method and use thereof

Growing community of inventors

Taizhou, China

Xiangyang Zhang